WA
ECYT

Wasatch Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Wasatch Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-64,242
Closed -$843K – 399
2013
Q2 		$843K Buy
+64,242
New +$866K 0.01% 358

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wasatch Advisors's ECYT Position: Q3 2013 in Review

Wasatch Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2013, closing a stake of 64,242 shares — an estimated $843K sold.

Wasatch Advisors first reported a position in ECYT in Q2 2013 and held it in 1 quarter. The position peaked at $843K in Q2 2013. 101 funds tracked by Wall St. Rank hold ECYT as of Q3 2013.

  • Wasatch Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Wasatch Advisors sold 64,242 Endocyte, Inc. Common Stock shares in Q3 2013, an estimated $843K.
  • Wasatch Advisors first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Wasatch Advisors's Endocyte, Inc. Common Stock position peaked at $843K in Q2 2013.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2013.

Based on Wasatch Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.